Plain-English translation of NCT06249282 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of two drugs— and —given together to treat advanced lung cancer in people whose cancer has a specific genetic mutation called KRASG12C. You would only qualify if your cancer has already been treated with another KRAS inhibitor and has progressed. The trial is designed to find the right dose of this combination and see how well it works and how safe it is.
Some people with this type of lung cancer stop responding to the first KRAS inhibitor they receive, and there aren't many good options left. This trial explores whether combining this medication with a different kind of drug might help people whose cancer has become resistant to standard KRAS treatment.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion on six days per month (days 1, 2, 8, 9, 15, and 16) and take as a daily pill for all 28 days of each cycle. Cycles repeat every 28 days as long as your cancer isn't progressing and you're tolerating the treatment well. You'll have regular blood tests, imaging scans (CT or MRI), an echocardiogram (heart ultrasound) at the start, and may have optional tumor biopsies to help researchers understand how the treatment works. The study involves about 15 patients total, and you'll be followed for safety for 30 days after treatment ends.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States